Bosentan-induced Reduction in Cyclosporine-A Levels: A Rare Interaction in an Infant With Osteopetrosis and Severe Pulmonary Hyperetension.
*Division of Clinical Pharmacy, School of Pharmacy, The Hebrew University Departments of †Pediatrics §Department of Pediatric Hematology-Oncology and Bone Marrow Transplantation ‡Pediatric Intensive Care Unit, Hadassah-Hebrew University Medical Center, Ein Kerem, Jerusalem, Israel ∥Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
Reem
R
Masarwa
Oded
O
Shamriz
Amir
A
Zilkha
Jacques
J
Braun
David M
DM
Kleid
Michael
M
Weintraub
Ansgar
A
Schulz
Polina
P
Stepensky
D000959:Antihypertensive Agents / Q000009:adverse effects*; D000077300:Bosentan; D016572:Cyclosporine / Q000097:blood* / Q000627:therapeutic use; D004347:Drug Interactions; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000097:blood* / Q000627:therapeutic use; D007223:Infant; D008297:Male; D010022:Osteopetrosis / Q000628:therapy*; D013449:Sulfonamides / Q000009:adverse effects*
D000959:Antihypertensive Agents; D007166:Immunosuppressive Agents; D013449:Sulfonamides; D016572:Cyclosporine; D000077300:Bosentan